The safety and efficacy of percutaneous intraductal radiofrequency ablation in unresectable malignant biliary obstruction: A single-institution experience.

Abstract:

BACKGROUND:Patients with unresectable malignant biliary obstruction have limited life expectancy because of limited stent patency and tumor progression. The aim of our study was to retrospectively evaluate the safety and efficacy of combining intraductal RFA with biliary metal stent placement for patients with malignant biliary obstruction. METHODS:Patients who received percutaneous intraductal RFA and biliary stent placement for malignant biliary obstruction between 2013 and 2015 were identified. Outcomes were stent patency, technique and clinical success rate, overall survival (OS) and complication rates. Kaplan-Meier and Cox regression analyses were used to examine the association of various factors with stent patency and OS. Complications and laboratory abnormalities were recorded. RESULTS:Fifty patients were treated with percutaneous RFA and stent placement. The rates of technical success and clinical success were 98% and 92%, respectively. The median stent patency was 7.0 (95% confidence interval [CI]: 5.3, 8.7) months and OS was 5.0 (95% CI: 4.0, 6.0) months. On univariable analysis, previously cholangitis was an independent poor prognosis factor for recurrent biliary obstruction. OS was improved in patients who received more than one intervention compared to those who received only one intervention (log-rank P = 0.007), and in those treated without versus those treated with sequential chemotherapy (log-rank P = 0.017). On multivariable analysis, the occurrence of more than one intervention (P = 0.019) had independent prognostic significance for OS. CONCLUSION:Percutaneous RFA and stent placement is a technically safe and feasible therapeutic option for the palliative treatment of malignant biliary obstruction. The long-term efficacy and safety of the procedure is promising, but further study is required via randomized and prospective trials.

journal_name

BMC Cancer

journal_title

BMC cancer

authors

Cui W,Fan W,Lu M,Zhang Y,Yao W,Li J,Wang Y

doi

10.1186/s12885-017-3278-5

subject

Has Abstract

pub_date

2017-04-24 00:00:00

pages

288

issue

1

issn

1471-2407

pii

10.1186/s12885-017-3278-5

journal_volume

17

pub_type

杂志文章
  • Prognostic factors for outcomes after whole-brain irradiation of brain metastases from relatively radioresistant tumors: a retrospective analysis.

    abstract:BACKGROUND:This study investigated potential prognostic factors in patients treated with whole-brain irradiation (WBI) alone for brain metastases from relatively radioresistant tumors such as malignant melanoma, renal cell carcinoma, and colorectal cancer. Additionally, a potential benefit from escalating the radiation...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-10-582

    authors: Meyners T,Heisterkamp C,Kueter JD,Veninga T,Stalpers LJ,Schild SE,Rades D

    更新日期:2010-10-26 00:00:00

  • Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.

    abstract:BACKGROUND:Crosstalk between malignant hepatocytes and the surrounding peritumoral stroma is a key modulator of hepatocarcinogenesis and therapeutic resistance. To examine the chemotherapy resistance of these two cellular compartments in vitro, we evaluated a well-established hepatic tumor cell line, HepG2, and an adul...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-12-402

    authors: Rangwala F,Williams KP,Smith GR,Thomas Z,Allensworth JL,Lyerly HK,Diehl AM,Morse MA,Devi GR

    更新日期:2012-09-10 00:00:00

  • A non-randomised, single-centre comparison of induction chemotherapy followed by radiochemotherapy versus concomitant chemotherapy with hyperfractionated radiotherapy in inoperable head and neck carcinomas.

    abstract:BACKGROUND:The application of induction chemotherapy failed to provide a consistent benefit for local control in primary treatment of advanced head and neck (H&N) cancers. The aim of this study was to compare the results of concomitant application of radiochemotherapy for treating locally advanced head-and-neck carcino...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-6-30

    authors: Graf R,Hildebrandt B,Tilly W,Riess H,Felix R,Budach V,Wust P

    更新日期:2006-02-01 00:00:00

  • MiR-890 inhibits proliferation and invasion and induces apoptosis in triple-negative breast cancer cells by targeting CD147.

    abstract:BACKGROUND:Triple-negative breast cancer (TNBC) is a type of breast cancer with a high degree of malignancy. Because of the remarkable biological characteristics of high invasion, metastasis and recurrence, TNBC is often accompanied by a poor prognosis. As a molecular characteristic of TNBC, high expression of CD147 ha...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-019-5796-9

    authors: Wang C,Xu C,Niu R,Hu G,Gu Z,Zhuang Z

    更新日期:2019-06-13 00:00:00

  • Factors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ.

    abstract:BACKGROUND:Invasion is often found during postoperative pathological examination of cases diagnosed as ductal carcinoma in situ (DCIS) by histological examinations such as core needle biopsy (CNB) or vacuum-assisted biopsy (VAB). A meta-analysis reported that 25.9% of invasive ductal carcinoma (IDC) cases are preoperat...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-020-07001-1

    authors: Takada K,Kashiwagi S,Asano Y,Goto W,Morisaki T,Takahashi K,Fujita H,Takashima T,Tomita S,Hirakawa K,Ohira M

    更新日期:2020-06-03 00:00:00

  • Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.

    abstract:BACKGROUND:After neoadjuvant chemoradiotherapy (nCRT) for esophageal cancer, high pathologically complete response (pCR) rates are being achieved especially in patients with squamous cell carcinoma (SCC). An active surveillance strategy has been proposed for SCC patients with clinically complete response (cCR) after nC...

    journal_title:BMC cancer

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1186/s12885-020-6669-y

    authors: Zhang X,Eyck BM,Yang Y,Liu J,Chao YK,Hou MM,Hung TM,Pang Q,Yu ZT,Jiang H,Law S,Wong I,Lam KO,van der Wilk BJ,van der Gaast A,Spaander MCW,Valkema R,Lagarde SM,Wijnhoven BPL,van Lanschot JJB,Li Z

    更新日期:2020-03-06 00:00:00

  • BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.

    abstract:BACKGROUND:The prognosis for patients with recurrent glioblastoma is still poor with a median survival between 3 and 6 months. Reports about the application of carmustine (BCNU), one of the standard chemotherapeutic drugs in the treatment of newly diagnosed glioblastoma, in the recurrent situation are rare. METHODS:We...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-10-30

    authors: Reithmeier T,Graf E,Piroth T,Trippel M,Pinsker MO,Nikkhah G

    更新日期:2010-02-02 00:00:00

  • Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis.

    abstract:BACKGROUND:Plasminogen activator inhibitor 1 (PAI-1) overexpression is an important prognostic and predictive biomarker in human breast cancer. SERBP1, a protein that is supposed to regulate the stability of PAI-1 mRNA, may play a role in gynaecological cancers as well, since upregulation of SERBP1 was described in ova...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-12-597

    authors: Serce NB,Boesl A,Klaman I,von Serényi S,Noetzel E,Press MF,Dimmler A,Hartmann A,Sehouli J,Knuechel R,Beckmann MW,Fasching PA,Dahl E

    更新日期:2012-12-13 00:00:00

  • Prognostic value of quality of life score in disease-free survivors of surgically-treated lung cancer.

    abstract:BACKGROUND:We aimed to evaluate the prognostic value of quality of life (QOL) for predicting survival among disease-free survivors of surgically-treated lung cancer after the completion of cancer treatment. METHODS:We administered the European Organization for Research and Treatment of Cancer Quality of Life Questionn...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-016-2504-x

    authors: Yun YH,Kim YA,Sim JA,Shin AS,Chang YJ,Lee J,Kim MS,Shim YM,Zo JL

    更新日期:2016-07-20 00:00:00

  • A genetic variant of the NTCP gene is associated with HBV infection status in a Chinese population.

    abstract:BACKGROUND:To investigate whether genetic variants of the HBV receptor gene NTCP are associated with HBV infection in the Han Chinese population. METHODS:We sequenced the entire 23 kb NTCP gene from 111 HBeAg-positive HBsAg carriers (PSE group), 110 HBeAg-negative HBsAg carriers (PS group), and 110 control subjects. T...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-016-2257-6

    authors: Yang J,Yang Y,Xia M,Wang L,Zhou W,Yang Y,Jiang Y,Wang H,Qian J,Jin L,Wang X

    更新日期:2016-03-12 00:00:00

  • (Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.

    abstract:BACKGROUND:Sorafenib is an orally active multikinase tyrosine kinase inhibitor (TKI) that targets B-type Raf kinase (BRAF), vascular endothelial growth factor receptors (VEGFR) 1 and 2, and rearranged during transfection (RET), inducing anti-angiogenic and pro-apoptotic actions in a wide range of solid tumors. A side e...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-016-2060-4

    authors: Schneider TC,Kapiteijn E,van Wezel T,Smit JWA,van der Hoeven JJM,Morreau H

    更新日期:2016-01-19 00:00:00

  • Diagnostic value of retrospective PET-MRI fusion in head-and-neck cancer.

    abstract:BACKGROUND:To assess the diagnostic value of retrospective PET-MRI fusion and to compare the results with side-by-side analysis and single modality use of PET and of MRI alone for locoregional tumour and nodal staging of head-and-neck cancer. METHODS:Thirty-three patients with head-and-neck cancer underwent preoperati...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-14-846

    authors: Loeffelbein DJ,Souvatzoglou M,Wankerl V,Dinges J,Ritschl LM,Mücke T,Pickhard A,Eiber M,Schwaiger M,Beer AJ

    更新日期:2014-11-19 00:00:00

  • The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters.

    abstract:BACKGROUND:SET domain containing protein 2 (SETD2) is a histone methyltransferase that is involved in transcriptional elongation. There is evidence that SETD2 interacts with p53 and selectively regulates its downstream genes. Therefore, it could be implicated in the process of carcinogenesis. Furthermore, this gene is ...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-9-290

    authors: Al Sarakbi W,Sasi W,Jiang WG,Roberts T,Newbold RF,Mokbel K

    更新日期:2009-08-21 00:00:00

  • Robot-assisted esophagectomy (RAE) versus conventional minimally invasive esophagectomy (MIE) for resectable esophageal squamous cell carcinoma: protocol for a multicenter prospective randomized controlled trial (RAMIE trial, robot-assisted minimally inva

    abstract:BACKGROUND:Currently, there are three main surgical approaches for resectable esophageal cancer: open transthoracic esophagectomy (OTE), conventional minimally invasive esophagectomy (MIE) and robot-assisted esophagectomy (RAE). Previous studies had demonstrated the better short-term outcomes in MIE or RAE when compare...

    journal_title:BMC cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1186/s12885-019-5799-6

    authors: Yang Y,Zhang X,Li B,Li Z,Sun Y,Mao T,Hua R,Yang Y,Guo X,He Y,Li H,Chen H,Tan L

    更新日期:2019-06-21 00:00:00

  • Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib.

    abstract:BACKGROUND:New therapeutic principles in clinical oncology require the adjustment of response criteria to govern therapy decisions. For advanced hepatocellular carcinoma (HCC) a new era has recently begun by the approval of the multikinase inhibitor sorafenib. As a unique feature, HCC usually develops in a diseased liv...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-9-208

    authors: Horger M,Lauer UM,Schraml C,Berg CP,Koppenhöfer U,Claussen CD,Gregor M,Bitzer M

    更新日期:2009-06-28 00:00:00

  • GENESIS: a French national resource to study the missing heritability of breast cancer.

    abstract:BACKGROUND:Less than 20% of familial breast cancer patients who undergo genetic testing for BRCA1 and BRCA2 carry a pathogenic mutation in one of these two genes. The GENESIS (GENE SISter) study was designed to identify new breast cancer susceptibility genes in women attending cancer genetics clinics and with no BRCA1/...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-015-2028-9

    authors: Sinilnikova OM,Dondon MG,Eon-Marchais S,Damiola F,Barjhoux L,Marcou M,Verny-Pierre C,Sornin V,Toulemonde L,Beauvallet J,Le Gal D,Mebirouk N,Belotti M,Caron O,Gauthier-Villars M,Coupier I,Buecher B,Lortholary A,Dugast

    更新日期:2016-01-12 00:00:00

  • Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.

    abstract:BACKGROUND:Platelets are frequently altered in hepatocellular carcinoma (HCC) patients. Platelet lysates (hPL) can enhance HCC cell growth and decrease apoptosis. The aims were to evaluate whether hPL can modulate the actions of sorafenib or regorafenib, two clinical HCC multikinase antagonists. METHODS:Several human ...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-14-351

    authors: D'Alessandro R,Refolo MG,Lippolis C,Giannuzzi G,Carella N,Messa C,Cavallini A,Carr BI

    更新日期:2014-05-21 00:00:00

  • Randomized controlled trial of an 8-week intervention combining self-care and hypnosis for post-treatment cancer patients: study protocol.

    abstract:BACKGROUND:Cancer has a lot of consequences on patients' quality of life (such as cancer-related fatigue (CRF), sleep difficulties and emotional distress) and on patients' partners and their relationship, such as distress and communication difficulties. These consequences are undertreated, and interventions based on hy...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-018-5046-6

    authors: Grégoire C,Faymonville ME,Vanhaudenhuyse A,Charland-Verville V,Jerusalem G,Bragard I

    更新日期:2018-11-15 00:00:00

  • Isothiocyanates induce oxidative stress and suppress the metastasis potential of human non-small cell lung cancer cells.

    abstract:BACKGROUND:Isothiocyanates are natural compounds found in consumable cruciferous vegetables. They have been shown to inhibit chemical carcinogenesis by a wide variety of chemical carcinogens in animal models. Recent studies have also shown that isothiocyanates have antitumor activity, inhibiting the growth of several t...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-10-269

    authors: Wu X,Zhu Y,Yan H,Liu B,Li Y,Zhou Q,Xu K

    更新日期:2010-06-09 00:00:00

  • Apoptosis inhibitor-5 overexpression is associated with tumor progression and poor prognosis in patients with cervical cancer.

    abstract:BACKGROUND:The apoptosis inhibitor-5 (API5), anti-apoptosis protein, is considered a key molecule in the tumor progression and malignant phenotype of tumor cells. Here, we investigated API5 expression in cervical cancer, its clinical significance, and its relationship with phosphorylated extracellular signal-regulated ...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-14-545

    authors: Cho H,Chung JY,Song KH,Noh KH,Kim BW,Chung EJ,Ylaya K,Kim JH,Kim TW,Hewitt SM,Kim JH

    更新日期:2014-07-28 00:00:00

  • A novel combined systemic inflammation-based score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization.

    abstract:BACKGROUND:There is currently limited information regarding the prognostic ability of the dNLR-PNI (the combination of the derived neutrophil-to-lymphocyte ratio [dNLR] and prognostic nutritional index [PNI]) for hepatocellular carcinoma (HCC). This study aimed to assess the predictive ability of the dNLR-PNI in patien...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-018-4121-3

    authors: Liu C,Li L,Lu WS,Du H,Yan LN,Wen TF,Wei WR,Jiang L,Xu MQ

    更新日期:2018-02-21 00:00:00

  • Meta-analysis of quantitative diffusion-weighted MR imaging in the differential diagnosis of breast lesions.

    abstract:BACKGROUND:To determine, in a meta-analysis, the diagnostic performance of quantitative diffusion-weighted (DW) MR imaging in patients with breast lesions. METHODS:English and Chinese studies published prior to June 2009 to assess the diagnostic performance of quantitative DWI in patients with breast lesions were revi...

    journal_title:BMC cancer

    pub_type: 杂志文章,meta分析

    doi:10.1186/1471-2407-10-693

    authors: Chen X,Li WL,Zhang YL,Wu Q,Guo YM,Bai ZL

    更新日期:2010-12-29 00:00:00

  • Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study.

    abstract:BACKGROUND:Microarray gene-profiling of invasive breast cancer has identified different subtypes including luminal A, luminal B, HER2-overexpressing and basal-like groups. Basal-like invasive breast cancer is associated with a worse prognosis. However, the prognosis of basal-like ductal carcinoma in situ (DCIS) is stil...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-10-653

    authors: Zhou W,Jirström K,Johansson C,Amini RM,Blomqvist C,Agbaje O,Wärnberg F

    更新日期:2010-11-30 00:00:00

  • ERO1α is a novel endogenous marker of hypoxia in human cancer cell lines.

    abstract:BACKGROUND:Hypoxia is an important factor that contributes to tumour aggressiveness and correlates with poor prognosis and resistance to conventional therapy. Therefore, identifying hypoxic environments within tumours is extremely useful for understanding cancer biology and developing novel therapeutic strategies. Seve...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-019-5727-9

    authors: Takei N,Yoneda A,Kosaka M,Sakai-Sawada K,Tamura Y

    更新日期:2019-05-29 00:00:00

  • Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database.

    abstract:BACKGROUND:The effect of current therapies in improving the survival of lung cancer patients remains far from satisfactory. It is consequently desirable to find more appropriate therapeutic opportunities based on informed insights. A molecular pharmacological analysis was undertaken to design an improved chemotherapeut...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/1471-2407-6-174

    authors: Gemma A,Li C,Sugiyama Y,Matsuda K,Seike Y,Kosaihira S,Minegishi Y,Noro R,Nara M,Seike M,Yoshimura A,Shionoya A,Kawakami A,Ogawa N,Uesaka H,Kudoh S

    更新日期:2006-06-30 00:00:00

  • Absence of an association of human polyomavirus and papillomavirus infection with lung cancer in China: a nested case-control study.

    abstract:BACKGROUND:Studies of human polyomavirus (HPyV) infection and lung cancer are limited and those regarding the association of human papillomavirus (HPV) infection and lung cancer have produced inconsistent results. METHODS:We conducted a nested case-control study to assess the association between incident lung cancer o...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-016-2381-3

    authors: Colombara DV,Manhart LE,Carter JJ,Hawes SE,Weiss NS,Hughes JP,Qiao YL,Taylor PR,Smith JS,Galloway DA

    更新日期:2016-06-01 00:00:00

  • A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol.

    abstract:BACKGROUND:Standard therapy for borderline-resectable pancreatic cancer in the UK is surgery with adjuvant chemotherapy, but rates of resection with clear margins are unsatisfactory and overall survival remains poor. Meta-analysis of single-arm studies shows the potential of neo-adjuvant chemo-radiotherapy but the rela...

    journal_title:BMC cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1186/s12885-016-2765-4

    authors: Holyoake DL,Ward E,Grose D,McIntosh D,Sebag-Montefiore D,Radhakrishna G,Patel N,Silva M,Mukherjee S,Strauss VY,Odondi L,Fokas E,Melcher A,Hawkins MA

    更新日期:2016-09-13 00:00:00

  • Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma.

    abstract:BACKGROUND:The variable prognosis in stage III cutaneous melanoma is partially due to unknown prognostic factors. Improved prognostic tools are required to define patients with an increased risk of developing metastatic disease who might benefit from adjuvant therapies. The aim was to examine if cellular immune markers...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-017-3577-x

    authors: Falkenius J,Johansson H,Tuominen R,Frostvik Stolt M,Hansson J,Egyhazi Brage S

    更新日期:2017-08-29 00:00:00

  • Adherence to quality breast cancer survivorship care in four Canadian provinces: a CanIMPACT retrospective cohort study.

    abstract:BACKGROUND:In order to maximize later health, there are established components and guidelines for quality follow-up care of breast cancer survivors. However, adherence to quality follow-up in Canada may not be optimal, and may vary by province. We determined and compared the proportion of patients in each province who ...

    journal_title:BMC cancer

    pub_type: 杂志文章

    doi:10.1186/s12885-019-5882-z

    authors: McBride ML,Groome PA,Decker K,Kendell C,Jiang L,Whitehead M,Li D,Grunfeld E,CanIMPACT Team.

    更新日期:2019-07-04 00:00:00

  • Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (WJOG

    abstract:BACKGROUND:Bevacizumab, a humanized antibody to vascular endothelial growth factor (VEGF), shows clinical activity against human cancer, with its addition to standard chemotherapy having been found to improve outcome in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). However, there have been no e...

    journal_title:BMC cancer

    pub_type: 杂志文章,随机对照试验

    doi:10.1186/1471-2407-12-327

    authors: Takeda M,Okamoto I,Yamanaka T,Nakagawa K,Nakanishi Y

    更新日期:2012-08-01 00:00:00